Comparison of MAG and Fish Oil Efficacy

Not Applicable

Completed

• Conditions: Obesity
• Interventions: Dietary Supplement: Fish oil enriched with EPA; Dietary Supplement: MAG-EPA oil; Drug: Orlistat

• Registration Number: NCT01797757
• Lead Sponsor: Société des Produits Nestlé (SPN)

Brief Summary

A potential application for unstructured monoacylglycerol (MAG) containing long chain polyunsaturated fatty acids (LC-PUFA)can be to provide essential fatty acids to humans who chronically consume lipases inhibitor such as Orlistat® for weigh lowering reasons. Indeed, it is predictable that chronic consumption of Orlistat® led to a depletion of essential fatty acids with time, therefore unstructured MAG containing LC-PUFA can be an option as a source of LC-PUFA for patients under Orlistat® treatment and hypothetically for subjects with other type of maldigestion/malabsorption. Potential applications of such concept are therefore related to disease conditions comprising low lipid digestion due to lipase activity insufficiency.

In the present study, in order to see the response information for eicosapentanoic acid (EPA) delivery, EPA will be provided either as a mixture of free monoacylglycerols or as triacylglycerol (TAG). The erythrocyte and plasma fatty acid composition from subjects under Orlistat® consumption will be analyzed.

Detailed Description

Not available

Study Timeline

• Study Start: 2012-01
• Primary Completion: 2012-09
• Study Completion: 2012-12
• Status Verified: 2013-02
• Study First Submitted: 2013-02-19
• Study First Submitted QC: 2013-02-21
• Last Update Submitted: 2013-02-21
• Study First Posted: 2013-02-22
• Last Update Posted: 2013-02-22

Recruitment & Eligibility

• Status: COMPLETED
• Sex: Female
• Target Recruitment: 46

Inclusion Criteria

• Age 18-65
• Sex female
• Body Mass Index (BMI) ≥ 30kg/m2 and < 40kg/m2
• Subjects willing to undergo treatment with Orlistat® (Xenical).
• Having obtained her written informed consent before any study related procedure including the pre-inclusion period.

Subject exclusion criteria:

• Binge eating disorder
• Any other weight loss treatment(s) within the last 3 months
• Vegetarians
• History of metabolic, cardiovascular, hepatic or renal diseases
• Obstructed bile duct
• Diseases that could interfere with intestinal absorption History of abdominal / gastric surgery (except appendicectomy)
• Use of drugs or illicit substances
• Consumption of alcohol > 50 gr/week
• Any other clinically significant abnormalities on screening laboratory evaluation (creatinine, Na, K, urique acide, ASAT, ALAT, Ph. Alc., yGT, Glycemia, total cholesterol, HDL, LDL, triglycerides) concentrations > 2.5 fold normal range
• Pregnant or lactating mothers
• Allergy to fish oil or other components (for e.g., gelatin or excepients of the capsule)
• Use of any other supplements containing fish oil for the duration of the trial or 3 month before inclusion in trial.
• Smokers
• Having donated blood or had a transfusion of blood/blood products during the trial and 3 months prior to screening or expected to do so during the study
• Bleeding disorders
• Subject who cannot be expected to comply with the study procedures.
• Currently participating or having participated in another clinical trial during last 8 weeks prior to the beginning of this study.

Read More

Exclusion Criteria

Not provided

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Fish oil enriched with EPA + ORLISTAT	Fish oil enriched with EPA	The oil will be liquid form of 1g /capsule. 3 capsules will be administrated per day: one capsule to be swallowed with a glass of water before every major meal, 3 times a day for 21 days. The Orlistat capsules of 120mg (except for groups 1 and 2). 3 capsules will be administrated per day: one capsule to be swallowed with a glass of water before every major meal, 3 times a day for 21 days.
Fish oil enriched with EPA + ORLISTAT	Orlistat	The oil will be liquid form of 1g /capsule. 3 capsules will be administrated per day: one capsule to be swallowed with a glass of water before every major meal, 3 times a day for 21 days. The Orlistat capsules of 120mg (except for groups 1 and 2). 3 capsules will be administrated per day: one capsule to be swallowed with a glass of water before every major meal, 3 times a day for 21 days.
MAG-EPA	MAG-EPA oil	The oil will be liquid form of 1g /capsule. 3 capsules will be administrated per day: one capsule to be swallowed with a glass of water before every major meal, 3 times a day for 21 days.
MAG-EPA + ORLISTAT	MAG-EPA oil	The oil will be liquid form of 1g /capsule. 3 capsules will be administrated per day: one capsule to be swallowed with a glass of water before every major meal, 3 times a day for 21 days. The Orlistat capsules of 120mg (except for groups 1 and 2). 3 capsules will be administrated per day: one capsule to be swallowed with a glass of water before every major meal, 3 times a day for 21 days.
MAG-EPA + ORLISTAT	Orlistat	The oil will be liquid form of 1g /capsule. 3 capsules will be administrated per day: one capsule to be swallowed with a glass of water before every major meal, 3 times a day for 21 days. The Orlistat capsules of 120mg (except for groups 1 and 2). 3 capsules will be administrated per day: one capsule to be swallowed with a glass of water before every major meal, 3 times a day for 21 days.
Fish oil enriched with EPA	Fish oil enriched with EPA	The oil will be liquid form of 1g /capsule. 3 capsules will be administrated per day: one capsule to be swallowed with a glass of water before every major meal, 3 times a day for 21 days.

Primary Outcome Measures

Name	Time	Method
The primary outcome will be accretion of EPA in erythrocytes at 21days	21 days

Secondary Outcome Measures

Name	Time	Method
• The secondary outcome will be the incorporation of EPA in plasma + chylomicrons	from baseline to day 21

Trial Locations

Locations (1)

CHUV Centre Hospitalier Universitaire Vaudois; 🇨🇭 Lausanne, Vaud, Switzerland